Key facts
- This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Jun 2021, 16:06.
Pascal Touchon - 25 Jun 2021 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)
- Issuer symbol
- ATRA
- Report date
- 25 Jun 2021
- Net transaction value
- -$231,660
- Form type
- 4
- Accepted by SEC
- 29 Jun 2021, 16:06:09 UTC
- Previous filing
- 20 May 2021
- Next filing
- 19 Aug 2021
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ David Tucker, Attorney-in-Fact for Pascal Touchon
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 29 Jun 2021.
Change
- Previous filing in this sequence was filed on 20 May 2021.
- Current net transaction value: -$231,660.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATRA
transaction
Common Stock
Sale
- Transaction value
- $231,660
- Shares
- -14,194
- Change %
- -4%
- Price
- $16.32*
- Shares after
- 345,114
- Date
- 25 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.